Nevirapina Aurobindo (Nevirapine)

Nevirapine binds to a non‑nucleoside site on the HIV‑1 reverse transcriptase enzyme, causing a conformational change that blocks the enzyme’s activity. This prevents the conversion of viral RNA into DNA, halting viral replication and reducing viral load.

The dosing regimen for nevirapine is individualized and must be determined by a qualified prescriber based on the patient’s age, weight, treatment history, and co‑medications. Patients should follow the specific instructions provided by their healthcare professional.

Nevirapine’s safety in pregnancy is classified as unknown, and it should only be used when the potential benefits outweigh the risks. Breastfeeding while on nevirapine is generally not recommended unless the infant’s HIV status has been confirmed and the benefits of therapy are deemed essential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Both nevirapine and efavirenz belong to the NNRTI class and suppress HIV replication by targeting reverse transcriptase. Nevirapine is often chosen for its lower central nervous system side‑effect profile, while efavirenz may have a higher risk of neuropsychiatric events. Selection depends on patient tolerance, drug‑interaction potential, and clinical guidelines.

Store the tablets at ambient temperature, preferably below 25 °C, in the original blister pack or container. Protect them from moisture, direct sunlight, and excessive heat to maintain potency throughout the shelf life.

Nevirapina Aurobindo is taken orally, usually with food to improve absorption and reduce gastrointestinal discomfort. The tablets should be swallowed whole with a full glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious adverse events include severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, and potentially life‑threatening hepatic failure. Early recognition of rash, jaundice, or flu‑like symptoms is essential, and patients should seek immediate medical attention if these occur.

Nevirapine is contraindicated in individuals with a known hypersensitivity to the drug or any of its components. It should also be avoided in patients with pre‑existing severe liver disease or those who have experienced severe rash or hepatic reactions to nevirapine in the past.